JP2011506447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506447A5 JP2011506447A5 JP2010537971A JP2010537971A JP2011506447A5 JP 2011506447 A5 JP2011506447 A5 JP 2011506447A5 JP 2010537971 A JP2010537971 A JP 2010537971A JP 2010537971 A JP2010537971 A JP 2010537971A JP 2011506447 A5 JP2011506447 A5 JP 2011506447A5
- Authority
- JP
- Japan
- Prior art keywords
- connexin
- agent
- polynucleotide
- pharmaceutical composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 56
- 108091033319 polynucleotide Proteins 0.000 claims description 56
- 239000002157 polynucleotide Substances 0.000 claims description 56
- 102000040430 polynucleotide Human genes 0.000 claims description 56
- 230000000692 anti-sense effect Effects 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 206010052428 Wound Diseases 0.000 claims description 27
- 208000027418 Wounds and injury Diseases 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- 230000001684 chronic effect Effects 0.000 claims description 17
- 239000000816 peptidomimetic Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- 102000001045 Connexin 43 Human genes 0.000 claims description 12
- 108010069241 Connexin 43 Proteins 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108091030071 RNAI Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 230000004962 physiological condition Effects 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 4
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 4
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 4
- 230000036573 scar formation Effects 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000003156 vasculitic effect Effects 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 8
- 102000010970 Connexin Human genes 0.000 claims 1
- 108050001175 Connexin Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US726207P | 2007-12-11 | 2007-12-11 | |
| PCT/US2008/013656 WO2009075882A2 (en) | 2007-12-11 | 2008-12-11 | Impaired wound healing compositions and treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097425A Division JP2014144976A (ja) | 2007-12-11 | 2014-05-09 | 損傷した創傷治癒組成物および治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506447A JP2011506447A (ja) | 2011-03-03 |
| JP2011506447A5 true JP2011506447A5 (OSRAM) | 2013-01-31 |
Family
ID=40626592
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537971A Withdrawn JP2011506447A (ja) | 2007-12-11 | 2008-12-11 | 損傷した創傷治癒組成物および治療 |
| JP2014097425A Withdrawn JP2014144976A (ja) | 2007-12-11 | 2014-05-09 | 損傷した創傷治癒組成物および治療 |
| JP2016082856A Pending JP2016135799A (ja) | 2007-12-11 | 2016-04-18 | 損傷した創傷治癒組成物および治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097425A Withdrawn JP2014144976A (ja) | 2007-12-11 | 2014-05-09 | 損傷した創傷治癒組成物および治療 |
| JP2016082856A Pending JP2016135799A (ja) | 2007-12-11 | 2016-04-18 | 損傷した創傷治癒組成物および治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100279921A1 (OSRAM) |
| EP (1) | EP2245158A2 (OSRAM) |
| JP (3) | JP2011506447A (OSRAM) |
| CN (2) | CN102920996A (OSRAM) |
| AU (2) | AU2008335718A1 (OSRAM) |
| CA (1) | CA2709153A1 (OSRAM) |
| WO (1) | WO2009075882A2 (OSRAM) |
| ZA (1) | ZA201004998B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006257283A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| CA2672220A1 (en) | 2006-12-11 | 2008-06-19 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| US20110245184A1 (en) * | 2007-12-21 | 2011-10-06 | Bradford James Duft | Treatment of surgical adhesions |
| WO2009085271A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
| WO2009085275A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
| JP2011507857A (ja) | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | 線維症性の状態の処置のためのコネキシン43の阻害剤の使用 |
| CA2710232A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
| WO2009085272A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
| CA2710227A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of surgical adhesions |
| JP6185937B2 (ja) | 2012-03-01 | 2017-08-23 | ファーストストリング・リサーチ・インコーポレイテッドFirststring Research,Inc. | アルファコネキシンc末端(act)ペプチド含有局所用ゲル剤 |
| US20140031753A1 (en) * | 2012-07-25 | 2014-01-30 | Neil T. Winthrop | Thoracostomy devices and methods of use |
| US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| CA2940648A1 (en) * | 2014-02-25 | 2015-09-03 | Coda Therapeutics, Inc. | Treatment of resistant lesions |
| US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| WO2018199777A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
| CN109513037B (zh) * | 2018-11-14 | 2021-09-17 | 华中科技大学同济医学院附属协和医院 | 一种负载介孔生物玻璃的小肠粘膜下层创面敷料 |
| WO2021119198A1 (en) * | 2019-12-09 | 2021-06-17 | Cage Bio, Inc. | Topical delivery of rna interference agents using ionic liquid |
| CN111214694B (zh) * | 2020-03-31 | 2022-04-22 | 山东大鱼生物技术有限公司 | 一种具有止血和加速伤口愈合功能的敷料及其制备方法 |
| CN116710474A (zh) | 2020-10-22 | 2023-09-05 | 撒凯尔生物公司 | 肽制剂及其眼科用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0539594Y2 (OSRAM) * | 1988-08-05 | 1993-10-07 | ||
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| ATE533515T1 (de) * | 1999-01-27 | 2011-12-15 | Coda Therapeutics Inc | Formulierungen enthaltend antisense nukleotide spezifisch für connexine |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| JP2005516054A (ja) * | 2002-01-29 | 2005-06-02 | ワイス | コネキシンヘミチャンネルを調節する組成物及びその方法 |
| EP1827480B1 (en) * | 2004-12-21 | 2016-11-09 | MUSC Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| AU2006257283A1 (en) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| RU2542471C2 (ru) * | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Улучшенные способы и композиции для заживления ран |
| CA2672220A1 (en) * | 2006-12-11 | 2008-06-19 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| CA2709151A1 (en) * | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| WO2009085271A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
| CA2710388A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars |
| US20110245184A1 (en) * | 2007-12-21 | 2011-10-06 | Bradford James Duft | Treatment of surgical adhesions |
| WO2009085275A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
| CA2711635A1 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
-
2008
- 2008-12-11 WO PCT/US2008/013656 patent/WO2009075882A2/en not_active Ceased
- 2008-12-11 AU AU2008335718A patent/AU2008335718A1/en not_active Abandoned
- 2008-12-11 US US12/747,863 patent/US20100279921A1/en not_active Abandoned
- 2008-12-11 CA CA2709153A patent/CA2709153A1/en not_active Abandoned
- 2008-12-11 EP EP08859398A patent/EP2245158A2/en not_active Withdrawn
- 2008-12-11 CN CN2012104108213A patent/CN102920996A/zh active Pending
- 2008-12-11 JP JP2010537971A patent/JP2011506447A/ja not_active Withdrawn
- 2008-12-11 CN CN2008801265360A patent/CN101970663A/zh active Pending
-
2010
- 2010-07-14 ZA ZA2010/04998A patent/ZA201004998B/en unknown
-
2014
- 2014-05-09 JP JP2014097425A patent/JP2014144976A/ja not_active Withdrawn
-
2015
- 2015-02-23 AU AU2015200904A patent/AU2015200904A1/en not_active Abandoned
-
2016
- 2016-04-18 JP JP2016082856A patent/JP2016135799A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506447A5 (OSRAM) | ||
| JP2011507860A5 (OSRAM) | ||
| JP2011508605A5 (OSRAM) | ||
| RU2009122370A (ru) | Улучшенные способы и композиции для заживления ран | |
| JP2011507858A5 (OSRAM) | ||
| JP2011507861A5 (OSRAM) | ||
| JP2022031772A5 (OSRAM) | ||
| JP2023123756A5 (OSRAM) | ||
| JP2011507855A5 (OSRAM) | ||
| CN102949709B (zh) | 一种治疗糖尿病足的外用凝胶剂及制备和应用 | |
| JP2010512404A5 (OSRAM) | ||
| JP2012041342A5 (OSRAM) | ||
| US8975237B2 (en) | Treatment of fibrotic conditions | |
| SA517381997B1 (ar) | تركيبة لتضميد الجرح | |
| US20110130710A1 (en) | Treatment of abnormal or excessive scars | |
| CA2730789A1 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| JP2019214592A (ja) | ベンダムスチンの製剤 | |
| RU2009126594A (ru) | Композиции и способы лечения плохо заживающих ран | |
| CN102920996A (zh) | 受损伤口愈合的药物组合物 | |
| JP2015083606A (ja) | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 | |
| KR20120014251A (ko) | 동종이식편의 접합을 개선하기 위한 생체활성 코팅 조성물 및 방법 | |
| JP6196704B2 (ja) | 神経因性疾病の治療のための医薬 | |
| CA2710227A1 (en) | Treatment of surgical adhesions | |
| JP2011507859A5 (OSRAM) | ||
| CN101896190A (zh) | 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤 |